La fibrose hépatique peut se développer en raison de l'inflammation chronique causée par la NAFLD.
FibroseInflammationStéatose hépatique
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque de la NAFLD ?
Les principaux facteurs incluent l'obésité, le diabète de type 2 et l'hyperlipidémie.
ObésitéDiabète de type 2Hyperlipidémie
#2
L'âge influence-t-il le risque de NAFLD ?
Oui, le risque de NAFLD augmente avec l'âge, surtout après 40 ans.
ÂgeStéatose hépatiqueFacteurs de risque
#3
Le sexe joue-t-il un rôle dans la NAFLD ?
Oui, les hommes sont généralement plus à risque de développer la NAFLD que les femmes.
SexeStéatose hépatiqueFacteurs de risque
#4
Le mode de vie sédentaire est-il un facteur de risque ?
Oui, un mode de vie sédentaire augmente le risque de NAFLD en favorisant l'obésité.
Mode de vie sédentaireObésitéStéatose hépatique
#5
Les antécédents familiaux influencent-ils le risque de NAFLD ?
Oui, des antécédents familiaux de maladies hépatiques augmentent le risque de NAFLD.
Antécédents familiauxStéatose hépatiqueFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Stéatose hépatique non alcoolique : Questions médicales les plus fréquentes",
"headline": "Stéatose hépatique non alcoolique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Stéatose hépatique non alcoolique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-15",
"dateModified": "2026-01-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Stéatose hépatique non alcoolique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Stéatose hépatique",
"url": "https://questionsmedicales.fr/mesh/D005234",
"about": {
"@type": "MedicalCondition",
"name": "Stéatose hépatique",
"code": {
"@type": "MedicalCode",
"code": "D005234",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.552.241"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Stéatose hépatique non alcoolique",
"alternateName": "Non-alcoholic Fatty Liver Disease",
"code": {
"@type": "MedicalCode",
"code": "D065626",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Atsushi Nakajima",
"url": "https://questionsmedicales.fr/author/Atsushi%20Nakajima",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan."
}
},
{
"@type": "Person",
"name": "Christopher D Byrne",
"url": "https://questionsmedicales.fr/author/Christopher%20D%20Byrne",
"affiliation": {
"@type": "Organization",
"name": "Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom."
}
},
{
"@type": "Person",
"name": "Vincent Wai-Sun Wong",
"url": "https://questionsmedicales.fr/author/Vincent%20Wai-Sun%20Wong",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Digestive Disease, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China."
}
},
{
"@type": "Person",
"name": "Wenhao Li",
"url": "https://questionsmedicales.fr/author/Wenhao%20Li",
"affiliation": {
"@type": "Organization",
"name": "Barts Liver Centre, London, UK."
}
},
{
"@type": "Person",
"name": "William Alazawi",
"url": "https://questionsmedicales.fr/author/William%20Alazawi",
"affiliation": {
"@type": "Organization",
"name": "Barts Liver Centre, London, UK w.alazawi@qmul.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease.",
"datePublished": "2023-12-02",
"url": "https://questionsmedicales.fr/article/38042817",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-023-01524-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.",
"datePublished": "2023-02-10",
"url": "https://questionsmedicales.fr/article/36839249",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu15040891"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease.",
"datePublished": "2023-05-03",
"url": "https://questionsmedicales.fr/article/37175909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24098203"
}
},
{
"@type": "ScholarlyArticle",
"name": "Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.",
"datePublished": "2023-04-13",
"url": "https://questionsmedicales.fr/article/37060912",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2468-1253(23)00066-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Validation of the Fatty Liver Index for identifying non-alcoholic fatty liver disease in a Kenyan population.",
"datePublished": "2023-08-31",
"url": "https://questionsmedicales.fr/article/37650501",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/tmi.13927"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004066"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du foie",
"item": "https://questionsmedicales.fr/mesh/D008107"
},
{
"@type": "ListItem",
"position": 4,
"name": "Stéatose hépatique",
"item": "https://questionsmedicales.fr/mesh/D005234"
},
{
"@type": "ListItem",
"position": 5,
"name": "Stéatose hépatique non alcoolique",
"item": "https://questionsmedicales.fr/mesh/D065626"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Stéatose hépatique non alcoolique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Stéatose hépatique non alcoolique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Stéatose hépatique non alcoolique",
"description": "Comment diagnostiquer la stéatose hépatique non alcoolique ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nL'échographie est-elle fiable pour diagnostiquer la NAFLD ?\nQuand une biopsie hépatique est-elle nécessaire ?\nQuels sont les critères de diagnostic de la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Stéatose hépatique non alcoolique",
"description": "Quels sont les symptômes courants de la NAFLD ?\nLa NAFLD provoque-t-elle des douleurs abdominales ?\nPeut-on avoir NAFLD sans symptômes ?\nQuels signes peuvent indiquer une progression de la NAFLD ?\nLa NAFLD peut-elle entraîner une perte de poids ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Stéatose hépatique non alcoolique",
"description": "Comment prévenir la NAFLD ?\nLe contrôle du diabète aide-t-il à prévenir la NAFLD ?\nL'alcool influence-t-il le risque de NAFLD ?\nLe stress a-t-il un impact sur la NAFLD ?\nLes bilans de santé réguliers aident-ils à prévenir la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Stéatose hépatique non alcoolique",
"description": "Quels traitements sont disponibles pour la NAFLD ?\nLes médicaments sont-ils efficaces contre la NAFLD ?\nComment l'alimentation influence-t-elle la NAFLD ?\nL'exercice physique aide-t-il à traiter la NAFLD ?\nLa perte de poids est-elle bénéfique pour la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Stéatose hépatique non alcoolique",
"description": "Quelles complications peuvent survenir avec la NAFLD ?\nLa NAFLD peut-elle entraîner une cirrhose ?\nQuels sont les risques de cancer associés à la NAFLD ?\nLa NAFLD augmente-t-elle le risque de maladies cardiovasculaires ?\nComment la fibrose est-elle liée à la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Stéatose hépatique non alcoolique",
"description": "Quels sont les principaux facteurs de risque de la NAFLD ?\nL'âge influence-t-il le risque de NAFLD ?\nLe sexe joue-t-il un rôle dans la NAFLD ?\nLe mode de vie sédentaire est-il un facteur de risque ?\nLes antécédents familiaux influencent-ils le risque de NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la stéatose hépatique non alcoolique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, échographies et parfois biopsies hépatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les transaminases, la bilirubine et les marqueurs de fibrose hépatique."
}
},
{
"@type": "Question",
"name": "L'échographie est-elle fiable pour diagnostiquer la NAFLD ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'échographie est un outil non invasif efficace pour détecter la graisse hépatique."
}
},
{
"@type": "Question",
"name": "Quand une biopsie hépatique est-elle nécessaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie est envisagée si la fibrose ou la stéatose sévère est suspectée."
}
},
{
"@type": "Question",
"name": "Quels sont les critères de diagnostic de la NAFLD ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent l'accumulation de graisse hépatique sans consommation d'alcool significative."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la NAFLD ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, mais peut inclure fatigue, douleur abdominale et inconfort."
}
},
{
"@type": "Question",
"name": "La NAFLD provoque-t-elle des douleurs abdominales ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent ressentir une douleur ou une gêne dans la partie supérieure droite."
}
},
{
"@type": "Question",
"name": "Peut-on avoir NAFLD sans symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, beaucoup de personnes sont asymptomatiques, rendant le diagnostic difficile."
}
},
{
"@type": "Question",
"name": "Quels signes peuvent indiquer une progression de la NAFLD ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de fibrose ou de cirrhose, comme l'ictère ou l'ascite, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "La NAFLD peut-elle entraîner une perte de poids ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la NAFLD est généralement associée à un gain de poids, mais des complications peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir la NAFLD ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé, adopter une alimentation équilibrée et faire de l'exercice régulièrement."
}
},
{
"@type": "Question",
"name": "Le contrôle du diabète aide-t-il à prévenir la NAFLD ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon contrôle de la glycémie réduit le risque de développer la NAFLD."
}
},
{
"@type": "Question",
"name": "L'alcool influence-t-il le risque de NAFLD ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que NAFLD ne soit pas causée par l'alcool, une consommation excessive peut aggraver la condition."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur la NAFLD ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut contribuer à des comportements alimentaires malsains, augmentant le risque de NAFLD."
}
},
{
"@type": "Question",
"name": "Les bilans de santé réguliers aident-ils à prévenir la NAFLD ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers permettent de détecter précocement des problèmes hépatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la NAFLD ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des changements de mode de vie, comme une alimentation saine et de l'exercice."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils efficaces contre la NAFLD ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiquement approuvés pour la NAFLD."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle la NAFLD ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et pauvre en graisses saturées peut réduire la graisse hépatique."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à traiter la NAFLD ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier aide à réduire la graisse hépatique et améliore la santé globale."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle bénéfique pour la NAFLD ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids de 5 à 10 % peut améliorer significativement la condition hépatique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la NAFLD ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la fibrose, la cirrhose et le cancer du foie."
}
},
{
"@type": "Question",
"name": "La NAFLD peut-elle entraîner une cirrhose ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la NAFLD peut progresser vers une cirrhose si elle n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de cancer associés à la NAFLD ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec NAFLD ont un risque accru de développer un cancer du foie."
}
},
{
"@type": "Question",
"name": "La NAFLD augmente-t-elle le risque de maladies cardiovasculaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la NAFLD est associée à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment la fibrose est-elle liée à la NAFLD ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fibrose hépatique peut se développer en raison de l'inflammation chronique causée par la NAFLD."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de la NAFLD ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'obésité, le diabète de type 2 et l'hyperlipidémie."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de NAFLD ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de NAFLD augmente avec l'âge, surtout après 40 ans."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans la NAFLD ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes sont généralement plus à risque de développer la NAFLD que les femmes."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire augmente le risque de NAFLD en favorisant l'obésité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque de NAFLD ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies hépatiques augmentent le risque de NAFLD."
}
}
]
}
]
}
Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, United Kingdom.
Publications dans "Stéatose hépatique non alcoolique" :
Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Digestive Disease, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Publications dans "Stéatose hépatique non alcoolique" :
Disease-related stress can trigger the occurrence of herpes zoster (HZ). Fatty liver disease (FLD) can have adverse effects on the human body and may induce stress in affected individuals. In this stu...
For this study, we utilized data from the National Health Insurance Research Database, patients with FLD from 2000 to 2017 were observed (follow-up until 2018). Patients were considered to have FLD if...
After 1:1 propensity-score matching, each cohort comprised 62,418 patients. The FLD cohort was further divided into NAFLD and AFLD groups, which respectively comprised 55,709 and 6709 patients. The FL...
Patients with FLD are at an increased risk of HZ development. Additionally, NAFLD is associated with a higher risk of HZ than AFLD. Therefore, patients with NAFLD should be informed of their increased...
With the increasing incidence of non-alcoholic fatty liver disease (NAFLD) and the aging of the population, sarcopenia is attracting attention as one of the pathological conditions involved in the dev...
Chronic liver disease (CLD) has emerged as a leading cause of human deaths. It caused 1.32 million deaths in 2017, which affected men more than women by a two-to-one ratio. There are various causes of...
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent form of chronic liver disease that poses challenges in diagnosis and risk stratification. Non-alcoholic steatohepatitis (NASH), the more...
Fatty Liver Index (FLI) is a simple clinical scoring system estimating non-alcoholic fatty liver disease (NAFLD). It is validated in European-descent and Asian populations, but not in sub-Saharan Afri...
Participants were recruited from a community-based study conducted in Kenya. NAFLD was diagnosed using hepatic ultrasonography. Clinical, anthropometrical, biochemical and lifestyle data were obtained...
A total of 640 participants (94 with NAFLD) were included. Mean age was 37.4 ± 0.4 years and 58.7% were women. Mean body mass index (BMI) was 22.3 ± 0.2 kg/m...
FLI is a simple valid scoring system to use in rural and urban Kenyan adults. However, this index might not be superior to BMI or WC to predict NAFLD, and those measurements might therefore be more ap...
Non-Alcoholic Fatty Liver Disease (NAFLD) refers to the accumulation of lipid laden vacuoles in hepatocytes, occurring in the context of visceral adiposity, insulin resistance and other features of th...
Individuals with lower levels of education are at a higher risk of developing various health conditions due to limited access to healthcare and unhealthy lifestyle choices. However, the association be...
This cross-sectional study included 8,727 participants from the Paracelsus 10,000 study. The association between NAFLD and educational level was assessed using multivariable logistic regression models...
In the study, NAFLD prevalence was 23% among participants with high education, 33% among intermediate, and 40% among those with low education (p<0.01). Importantly, a significantly reduced risk of NAF...
The study's findings indicate that a lower education level increases the risk of NAFLD independent of confounding factors. Therefore, these findings highlight the potential impact of educational attai...
Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD). However, different effects of pioglitazone on NAFLD have been demonstrated in diabetic and non-diabetic pa...
Randomized controlled trials (RCTs) of pioglitazone...
The review covered seven articles, with 614 patients in total, of which three were non-diabetic RCTs. No difference was found in patients with...
Pioglitazone could exert a certain effect on alleviating NAFLD, which was consistent between non-diabetic NAFLD patients and diabetic NAFLD patients in improving histopathology, liver enzymes, and HOM...
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common liver disease worldwide, affecting an estimated 3 in 10...
To evaluate the beneficial and harmful effects of vitamin E alone, or vitamin E in combination with other vitamins or minerals, versus placebo or no intervention in people with NAFLD....
We used recommended Cochrane search methods. The latest search was performed on 2 February 2024....
We included randomised clinical trials that compared vitamin E alone, or in combination with other vitamins or minerals, at any dose, duration, and route of administration, versus placebo or no interv...
Our critical outcomes were all-cause mortality, liver-related mortality, and serious adverse events. Our important outcomes were liver-related morbidity, health-related quality of life, non-serious ad...
We used Cochrane's RoB 2 tool to assess risk of bias for each of the predefined outcomes....
We used standard Cochrane methods. We used GRADE to assess the certainty of evidence....
We included 16 randomised clinical trials involving 1066 paediatric and adult participants with NAFLD. Experimental groups received vitamin E alone (14 trials) or vitamin E in combination with vitamin...
Vitamin E versus placebo or no intervention The effects of vitamin E versus placebo or no intervention on all-cause mortality (risk ratio (RR) 3.45, 95% confidence interval (CI) 0.57 to 20.86; 3 trial...
Given the very low certainty evidence, we do not know if long-term treatment (18 months to 24 months) with vitamin E administered alone affects all-cause mortality, serious adverse events, quality of ...
Three trials disclosed no external funding. Five trials were industry funded. Five trials were funded by organisations with no vested interests. Three trials did not provide any information on clinica...
Protocol: doi.org/10.1002/14651858.CD015033....
Non-alcoholic fatty liver disease (NAFLD) refers to a range of conditions in which excess lipids accumulate in the liver, possibly leading to serious hepatic manifestations such as steatohepatitis, fi...
